Literature DB >> 11581236

Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.

L Zhang1, X Z Li, K Poole.   

Abstract

The antibacterial activities of seven fluoroquinolones (ciprofloxacin, BAYy3118, clinafloxacin, gemifloxacin, moxifloxacin, sparfloxacin and trovafloxacin) against isogenic efflux-mediated multidrug-resistant strains of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia, were compared. The results indicate that these fluoroquinolones are all substrates for the multidrug efflux systems of these organisms. Clinafloxacin was found generally to be the most active agent against multidrug-resistant strains.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11581236     DOI： 10.1093/jac/48.4.549

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  17 in total

1.  In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.

Authors:  Evangelos J Giamarellos-Bourboulis; Lazaros Karnesis; Irene Galani; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 2.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

3.  Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients.

Authors:  B Saugel; K Eschermann; R Hoffmann; A Hapfelmeier; C Schultheiss; V Phillip; F Eyer; K-L Laugwitz; R M Schmid; W Huber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-07       Impact factor: 3.267

4.  Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient.

Authors:  Akshu Balwan; David P Nicolau; Minkey Wungwattana; Jonathan B Zuckerman; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2015-12-31       Impact factor: 5.191

5.  Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.

Authors:  Catherine Llanes; Thilo Köhler; Isabelle Patry; Barbara Dehecq; Christian van Delden; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

6.  Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity.

Authors:  Fatima Kamal; Jonathan J Dennis
Journal:  Appl Environ Microbiol       Date:  2014-12-01       Impact factor: 4.792

7.  Salicylate induces an antibiotic efflux pump in Burkholderia cepacia complex genomovar III (B. cenocepacia).

Authors:  Bindu M Nair; K-John Cheung; Adam Griffith; Jane L Burns
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

8.  The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients.

Authors:  Matthew T G Holden; Helena M B Seth-Smith; Lisa C Crossman; Mohammed Sebaihia; Stephen D Bentley; Ana M Cerdeño-Tárraga; Nicholas R Thomson; Nathalie Bason; Michael A Quail; Sarah Sharp; Inna Cherevach; Carol Churcher; Ian Goodhead; Heidi Hauser; Nancy Holroyd; Karen Mungall; Paul Scott; Danielle Walker; Brian White; Helen Rose; Pernille Iversen; Dalila Mil-Homens; Eduardo P C Rocha; Arsenio M Fialho; Adam Baldwin; Christopher Dowson; Bart G Barrell; John R Govan; Peter Vandamme; C Anthony Hart; Eshwar Mahenthiralingam; Julian Parkhill
Journal:  J Bacteriol       Date:  2008-10-17       Impact factor: 3.490

Review 9.  Efflux-mediated drug resistance in bacteria.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Boubakar B Ba; Hala Feghali; Corinne Arpin; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.